MVRBF - Medivir AB GAAP EPS of -SEK 0.32 net turnover of SEK 2.3M
- Medivir AB press release ( OTC:MVRBF ): Q4 GAAP EPS of -SEK 0.32.
- Net turnover of SEK 2.3M (-83.5% Y/Y).
- Liquid assets, including short-term investments amounted to SEK 117.4M at the end of the period, corresponding to a decrease of SEK 103.7M.
- The board proposes that no dividend be paid for the 2022 financial year.
- Outlook: Medivir’s future investments will mainly be in clinical pharmaceutical projects within oncology. It is the assessment of the Board and management that existing cash and cash equivalents are sufficient to cover the company's needs to complete the ongoing phase 1b study as well as one combination arm in phase 2a.
For further details see:
Medivir AB GAAP EPS of -SEK 0.32, net turnover of SEK 2.3M